Capital Cell is Europe's first online investment platform specialising in biomedicine. Despite the global coronavirus pandemic, it has raised 4 million euros of investment for 4 companies in the first quarter of 2020. The coronavirus crisis is hitting the global economy hard, especially in our country.
After a tough quarter for the markets, investment funds have opted to bet on biomedical high-tech companies, a sector in full bloom in Spain. This is the case of Cell Capital.
According to Capital Cell CEO Daniel Oliver"In a context such as the current one, the importance of biotechnology goes from being strategic to being urgent, and it is going to establish itself as one of the most desirable investment sectors". The investment made by Capital Cell alone would represent more than 12% of the total investment made in the biotechnology sector in Spain in 2018, which amounted to €98 million according to the Spanish Association of Biotechnology Companies.
However, it is not only Spain that is experiencing a growth in the investment in biotechnology. Between February and March, the biotech sector was the best performing investment in the US NASDAQ index, while most other investment sectors, including financials, energy and real estate, recorded historic declines.
The online investment platform specialising in biomedicine invested four million euros in four companies in the biotech sector in the first quarter of this year, which is 37% more than in the same period last year. It is also more than a third of the total invested last year, as €11.6m was moved in 2019.
For example, since the start of the Covid-19 crisis confinement, Capital Cell has successfully launched and closed a ¤560,000 investment round for Valencian digital diagnostic system companyeKuore. Also other start-ups such asAortyx,DevicareoAbility Pharma6 million have been confirmed.